I Gusti Ngurah Agung Wiwekananda, Nik Ahmad Nizam Nik Malek, Agustina Tri Endharti, Happy Kurnia Permatasari
Cervical cancer remains a major global health burden, particularly in advanced and recurrent disease, where therapeutic options are limited. We conducted a systematic review of clinical studies evaluating nab-paclitaxel–based regimens in cervical cancer, following PRISMA 2020 guidelines. Literature published between 2015 and 2025 was identified across five databases, and risk of bias was assessed using the MINORS tool. Ten studies (five single-arm and five comparative; n = 417) were included. Nab-paclitaxel was administered in combination with chemotherapy, radiotherapy, or immunotherapy. Across single-arm studies, objective response rates ranged from 40% to 57%, with median progression-free survival of 4.5–9.1 months and overall survival of 8.9–16.6 months. Comparative studies suggested higher response rates with nab-paclitaxel–cisplatin regimens, particularly in neoadjuvant settings. Nab-paclitaxel–based combinations demonstrated generally manageable toxicity. However, interpretation is limited by study heterogeneity and the absence of randomized controlled trials. © 2026 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.
Biomedical Science Master Program, Faculty of Medicine, Universitas Brawijaya, Malang, Indonesia; Department of Biosciences, Faculty of Science, Universiti Teknologi Malaysia, Johor, Skudai, Malaysia; Centre of Sustainable Nanomaterials, Ibnu Sina Institute for Scientific and Industrial Research, Universiti Teknologi Malaysia, Johor, Skudai, Malaysia; Department of Parasitology, Faculty of Medicine, Universitas Brawijaya, Malang, Indonesia; Department of Biochemistry and Biomolecular, Faculty of Medicine, Universitas Brawijaya, Malang, Indonesia
